JLL to acquire pharmaceutical developerThe New York-based private equity firm will purchase the outstanding shares of PharmaNet Development Group for $5 a share in a deal valued at close to $100 million.ByKevin Ley5 January 2013•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.Deals
